Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Oct 9;10(10):CD002122.
doi: 10.1002/14651858.CD002122.pub3.

Progestagens for pain symptoms associated with endometriosis

Innie Chen  1   2   3 , Sari Kives  4 , Andrew Zakhari  5 , Dong Bach Nguyen  5 , Hanna R Goldberg  4 , Abdul J Choudhry  3 , Ai-Lien Le  3 , Emilie Kowalczewski  3 , Jeppe Bennekou Schroll  6   7   8
Affiliations
Meta-Analysis

Progestagens for pain symptoms associated with endometriosis

Innie Chen et al. Cochrane Database Syst Rev. .

Abstract

Background: Endometriosis is a hormone-sensitive inflammatory condition affecting between 5% and 10% of reproductive-aged women and an unknown number of gender-diverse individuals. It is often associated with debilitating pelvic pain symptoms. Various formulations of progestagens (e.g. oral, depot, implantable) have been studied as potential treatments for endometriosis because they induce atrophy of endometrial tissue.

Objectives: To determine the benefits and harms of progestagens in the treatment of endometriosis-associated pain symptoms.

Search methods: We searched CENTRAL, MEDLINE, Embase, and PsycINFO on 29 October 2024 without language restrictions.

Selection criteria: We included randomised controlled trials (RCTs) comparing progestagens for symptomatic endometriosis against placebo, other medications, or different doses of progestagens. Studies assessing the levonorgestrel-releasing intrauterine device were ineligible, as a separate Cochrane review covers this intervention. Participants were of reproductive age with a laparoscopic diagnosis of endometriosis and associated pain symptoms. Primary outcomes included endometriosis-associated pain symptoms (overall pain, pelvic pain, and dysmenorrhoea). Secondary outcomes included quality of life, patient satisfaction, and adverse effects.

Data collection and analysis: At least two review authors independently selected studies, extracted data, and assessed risk of bias. We reported dichotomous outcomes as risk ratios (RRs) and continuous outcomes as mean differences (MDs), each with its corresponding 95% confidence interval (CI). The meta-analysis employed a fixed-effect model, and we assessed statistical heterogeneity using the I2 statistic. We used GRADE to assess evidence certainty.

Main results: We included 33 RCTs involving 5059 participants with symptomatic, laparoscopically diagnosed endometriosis. We judged 13 studies at overall low risk of bias. The following comparisons are limited by the small number of studies reporting each outcome. Pain outcomes, quality of life, and patient satisfaction were measured at six months unless otherwise specified. Oral progestagens versus placebo or no treatment (8 studies) Oral progestagens compared with placebo probably reduce overall pain measured on a visual analogue scale (VAS; MD -2.58, 95% CI -3.13 to -2.03; moderate certainty), and probably reduce dysmenorrhoea at three months (RR 0.21, 95% CI 0.07 to 0.70, moderate certainty), but may have little to no effect on pelvic pain at three months (RR 0.7, 95% CI 0.29 to 1.69; low certainty). Oral progestagens improve quality of life (SF-36 score; MD 4.11, 95% CI 2.41 to 5.82, high certainty). There is probably little to no difference between the interventions in study withdrawal due to adverse effects (RR 2.36, CI 0.74 to 7.52, moderate certainty) and cumulative side effects (RR 1.18, 95% CI 0.94 to 1.46, moderate certainty). Oral progestagens versus oral contraceptives (4 studies) Oral progestagens compared with oral contraceptives probably have little to no effect on pelvic pain measured on a VAS (MD 0.38, 95% CI -0.46 to 1.22, moderate certainty). There was very low-certainty evidence about their effect on dysmenorrhoea at 12 months (MD -0.57, 95% CI -1.29 to 0.15), quality of life (SF-36 general health perception; MD 5.2, 95% CI -1.3 to 11.70), and patient satisfaction (RR 1.18, 95% CI 0.88 to 1.57). Oral progestagens may lead to better quality of life (SF-36 pain score; MD 11.5, 95% CI 2.35 to 20.65, low certainty). There may be little to no difference between oral progestagens and oral contraceptives in study withdrawal due to adverse effects (RR 0.75, 95% CI 0.27 to 2.07, low certainty), and there is probably little to no difference in cumulative side effects (RR 1.13, 95% CI 0.8 to 1.60, moderate certainty). Oral progestagens versus gonadotropin-releasing hormone (GnRH) agonists (10 studies) Oral progestagens compared with GnRH agonists may have little to no effect on overall pain measured on a VAS (MD -0.01, 95% CI -0.30 to 0.28), risk of pelvic pain (RR 1.12, 95% CI 0.80 to 1.59), dysmenorrhoea (RR 1.45, 95% CI 0.71 to 3.00), SF-36 physical health score (MD 0.40, 95% CI -1.58 to 2.38), SF-36 mental health score (MD -0.50, 95% CI -3.75 to 2.75), patient satisfaction (RR 1.08, 95% CI 0.92 to 1.26), and study withdrawal due to adverse effects (RR 0.9, 95% CI 0.34 to 2.43). All these outcomes had low-certainty evidence. The risk of cumulative side effects was probably higher with oral progestagens (RR 1.44, 95% CI 1.11 to 1.86, moderate certainty). Depot progestagens versus GnRH agonists (2 studies) Depot progestagens compared with GnRH agonists reduce dysmenorrhoea risk slightly (RR 0.93, 95% CI 0.89 to 0.97, high certainty) but may have little to no effect on pelvic pain (RR 0.96, 95% CI 0.87 to 1.07, low certainty). The interventions may be similar in study withdrawal due to adverse effects (RR 1.41, 95% CI 0.24 to 8.32, low certainty), but the risk of cumulative side effects is probably lower with depot progestagens (RR 0.03, 95% CI 0.01 to 0.11, moderate certainty). Depot progestagens versus GnRH antagonist (1 study) Depot progestagens compared with GNRH agonists may have little to no effect on pelvic pain (RR 0.85, 95% CI 0.7 to 1.03, low certainty), dysmenorrhoea (RR 0.85, 95% CI 0.7 to 1.03, low certainty), and cumulative adverse effects (RR 1.04, 0.95 to 1.14, low certainty). Study withdrawal due to side effects is likely higher with depot progestagens (RR 2.02, 95% CI 1.04 to 3.94, moderate certainty). Depot progestagens versus the etonogestrel implant (1 study) There was very low-certainty evidence about the effect of depot progestagens versus the etonogestrel implant on overall pain measured on a VAS (MD 0.80, 95% CI - 0.42 to 2.02), patient satisfaction (RR 0.96, 95% CI 0.56 to 1.66), and study withdrawal due to adverse effects (RR 1.84, 95% CI 0.63 to 5.33).

Authors' conclusions: In individuals with endometriosis, oral progestagens compared with placebo likely reduce overall pain and dysmenorrhoea and may reduce pelvic pain. Compared with other hormonal suppression strategies, the evidence is less certain due to the small number of studies for each comparison and outcome. Despite such limitations, this update provides a comprehensive overview and valuable insights on progestagen treatment for endometriosis, emphasising the nuanced balance between efficacy, adverse effects, and patient satisfaction.

Trial registration: ClinicalTrials.gov NCT04500743 NCT01559480 NCT02271958.

PubMed Disclaimer

Conflict of interest statement

IC: Dr Chen is a gynaecologist with subspecialty focus on minimally invasive gynaecologic surgery and serving patients with menstrual pain and bleeding disorders. She is a Member of the Board of the International Pelvic Pain Society. She served on the Society of Obstetricians and Gynecologists of Canada (SOGC) Clinical Practice Gynecology Committee and serves on the AAGL Practice Committee, and she is an author on national clinical practice guidelines on the management of chronic pelvic pain. SK: no interests to disclose. AZ: No interests to disclose. DN: Dr. Dong Bach Nguyen is an Obstetrician‐Gynaecologist at the McGill University Health Centre. He has received an honorarium for presentations from AbbVie. No other interests to disclose. HG: no interests to disclose. AC: no interests to disclose. AL: no interests to disclose. EK: no interests to disclose. JS: no interests to disclose.

Update of

References

References to studies included in this review

Abdou 2018 {published data only}
    1. Abdou AM, Ammar IM, Alnemr AA, Abdelrhman AA. Dienogest versus leuprolide acetate for recurrent pelvic pain following laparoscopic treatment of endometriosis. Journal of Obstetrics and Gynecology of India 2018;68(4):306-13. [PMID: ] - PMC - PubMed
Bergqvist 2001 {published data only}
    1. Bergqvist A, Thorell T. Changes in quality of life after hormonal treatment for endometriosis. Acta Obstetricia et Gynecologica Scandinavica 2001;80:628-37.
Carr 2014 {published data only}
    1. Carr B, Dmowski WP, O'Brien C, Jiang P, Burke J, Jimenez R, et al. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for the treatment of endometriosis: effects on bone mineral density. Reproductive Sciences (Thousand Oaks, Calif.) 2014;21(11):1341-51. [PMID: ] - PMC - PubMed
Ceccaroni 2021 {published data only}
    1. Ceccaroni M, Clarizia R, Liverani S, Donati A, Ceccarello M, Manzone M, et al. Dienogest vs GnRH agonists as postoperative therapy after laparoscopic eradication of deep infiltrating endometriosis with bowel and parametrial surgery: a randomized controlled trial. Gynecological Endocrinology 2021;37(10):930-3.
Cheewadhanaraks 2009 {published data only}
    1. Cheewadhanaraks S, Peeyananjarassri K, Choksuchat C, Dhanaworavibul K, Choobun T, Bunyapipat S. Interval of injections of intramuscular depot medroxyprogesterone acetate in the long-term treatment of endometriosis-associated pain: a randomized comparative trial. Gynecologic and Obstetric Investigation 2009;68(2):116-21. [PMID: ] - PubMed
Cheewadhanaraks 2012 {published data only}
    1. Cheewadhanaraks S, Choksuchat C, Dhanaworavibul K, Liabsuetrakul T. Postoperative depot medroxyprogesterone acetate versus continuous oral contraceptive pills in the treatment of endometriosis-associated pain: a randomized comparative trial. Gynecologic and Obstetric Investigation 2012;74(2):151-6. [PMID: ] - PubMed
Cosson 2002 {published data only}
    1. Cosson M, Querleu D, Donnez J, Madelenat P, Koninckx P, Audebert A, et al. Dienogest is as effective as triptorelin in the treatment of endometriosis after laparoscopic surgery: results of a prospective, multicenter, randomized study. Fertility and Sterility 2002;77(4):684-92. [PMID: ] - PubMed
Crosignani 2006 {published data only}
    1. Crosignani PG, Luciano A, Ray A, Bergqvist A. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the treatment of endometriosis-associated pain. Human Reproduction 2006;21(1):248-56. [PMID: ] - PubMed
DiVasta 2021 {published data only}
    1. DiVasta AD, Stamoulis C, Gallagher JS, Laufer MR, Anchan R, Hornstein MD. Nonhormonal therapy for endometriosis: a randomized, placebo-controlled, pilot study of cabergoline versus norethindrone acetate. F&S Reports 2021;2(4):454-61.
El Taha 2021 {published data only}
    1. El Taha L, Abu Musa A, Khalifeh D, Khalil A, Abbasi S, Nassif J. Efficacy of dienogest vs combined oral contraceptive on pain associated with endometriosis: randomized clinical trial. European Journal of Obstetrics and Gynecology and Reproductive Biology 2021;267:205-12.
Harada 2009 {published data only}
    1. Harada T, Momoeda M, Taketani Y, Takeshi A, Fukunaga M, Hagino H, et al. Dienogest is as effective as intranasal buserelin acetate for the relief of pain symptoms associated with endometriosis - a randomized, double blind, multi-centre trial. Fertility and Sterility 2009;91(3):675-81.
Harrison 2000 {published data only}
    1. Harrison RF, Barry-Kinsella C. Efficacy of medroxyprogesterone treatment in infertile women with endometriosis: a prospective, randomized, placebo-controlled study. Fertility and Sterility 2000;74(1):24-30. [PMID: ] - PubMed
Kashi 2022 {published data only}
    1. Mehdizadeh Kashi A, Niakan G, Ebrahimpour M, et al. A randomized, double-blind, placebo-controlled pilot study of the comparative effects of dienogest and the combined oral contraceptive pill in women with endometriosis. International Journal of Gynecology & Obstetrics 2022;156:124-32.
    1. Niakan G, Rokhgireh S, Ebrahimpour M, Mehdizadeh Kashi A. Comparing the effect of dienogest and OCPS on pain and quality of life in women with endometriosis: a randomized, double-blind, placebo-controlled trial. Archives of Iranian Medicine 2021;24(9):670-7.
Khalifa 2021 {published data only}
    1. Khalifa E, Mohammad H, Abdullah A, Abdel-Rasheed M, Khairy M, Hosni M. Role of suppression of endometriosis with progestins before IVF-ET: a non-inferiority randomized controlled trial. BMC Pregnancy and Childbirth 2021;21(1):264. [PMCID: PMC8011082] [PMID: ] - PMC - PubMed
Kohler 2010 {published data only}
    1. Köhler G, Faustmann TA, Gerlinger C, Seitz C, Mueck AO. A dose-ranging study to determine the efficacy and safety of 1, 2, and 4mg of dienogest daily for endometriosis. International Journal of Gynecology & Obstetrics 2010;108(1):21-5. [PMID: ] - PubMed
Kyal 2018 {published data only}
    1. Kyal A, Pal A, Mukhopadhyay A, Mukhopadhyay P. Does cabergoline help in decreasing chronic pelvic pain due to endometriosis compared to medroxyprogesterone acetate? A prospective randomized study. Journal of South Asian Federation of Obstetrics and Gynaecology 2018;10(3):167-9.
Lang 2018 {published data only}
    1. Lang J, Yu Q, Zhang S, Li H, Gude K, Ludwig C, et al. Dienogest for treatment of endometriosis in Chinese women: a placebo-controlled, randomized, double-blind phase 3 study. Journal of Women's Health 2018;27(2):148-55.
    1. Yu Q, Zhang S, Li H, Wang P, Zvolanek M, Ren X, et al. Dienogest for treatment of endometriosis in women: a 28-week, open-label, extension study. Journal of Women's Health 2019;2:170-7.
Overton 1994 {published data only}
    1. Overton CE, Lindsay PC, Johal B. A randomised, double-blind, placebo controlled study of luteal phase dydrogesterone (Duphaston) in women with minimal to mild endometriosis. Fertility and Sterility 1994;62(4):701-7.
Razzi 2007 {published data only}
    1. Razzi S, Luisi S, Ferretti C, Calonaci F, Gabbanini M, Mazzini M, et al. Use of progestogen only preparation containing desogestrel in the treatment of recurrent pelvic pain after conservative surgery for endometriosis. European Journal of Obstetrics and Gynecology 2007;135:188-90.
Regidor 2001 {published data only}
    1. Regidor PA, Regidor M, Schmidt M, Ruwe B, Lübben G, Förtig P, et al. Prospective randomized study comparing the GnRH-agonist leuprorelin acetate and the gestagen lynestrenol in the treatment of severe endometriosis. Gynecological Endocrinology 2001;15(3):202-9. [PMID: ] - PubMed
Schlaff 2006 {published data only}
    1. Sclaff W, Carson S, Luciano A, Ross D, Bergvist A. Subcutaneous injection of depot medoxyprogesterone acetate compared with leuprolide acetate in the treatment of endometriosis associated pain. Fertility and Sterility 2006;85(2):314-25.
Strowitzki 2010 {published data only}
    1. Strowitzki T, Faustmann T, Gerlinger C, Seitz C. Dienogest in the treatment of endometriosis-associated pelvic pain: a 12-week, randomized, double-blind, placebo-controlled study. European Journal of Obstetrics, Gynecology, and Reproductive Biology 2010;151(2):193-8. [PMID: ] - PubMed
Strowitzki 2012 {published data only}
    1. Strowitzki T, Marr J, Gerlinger C, Faustmann T, Seitz C. Detailed analysis of a randomized, multicenter, comparative trial of dienogest versus leuprolide acetate in endometriosis. International Journal of Gynaecology and Obstetrics 2012;117(3):228-33. [DOI: 10.1016/j.ijgo.2012.01.009] [PMID: ] - DOI - PubMed
    1. Strowitzki T, Marr J, Gerlinger C, Faustmann T, Seitz C. Dienogest is as effective as leuprolide acetate in treating the painful symptoms of endometriosis: a 24 week, randomized, multicentre, open-label trial. Human Reproduction (Oxford, England) 2010;25(3):633-41.
Takaesu 2016 {published data only}
    1. Takaesu Y, Nishi H, Kojima J, Sasaki T, Nagamitsu Y, Kato R, et al. Dienogest compared with gonadotropin-releasing hormone agonist after conservative surgery for endometriosis. Journal of Obstetrics and Gynaecology Research 2016;42(9):1152-8. [PMID: ] - PubMed
Tang 2023 {published data only}
    1. Tang M, Yang W, Zhang H. Comparison of the efficacy of dienogest and GnRH-a after endometriosis surgery. BMC Women's Health 2023;23(1):85. [PMID: ] - PMC - PubMed
Tanmahasamut 2017 {published data only}
    1. Tanmahasamut P, Saejong R, Rattanachaiyanont M, Angsuwathana S, Techatraisak K, Sanga-Areekul N. Postoperative desogestrel for pelvic endometriosis-related pain: a randomized controlled trial. Gynecological Endocrinology 2017;33(7):534-9. [PMID: ] - PubMed
Telimaa 1987 {published and unpublished data}
    1. Kauppila A, Telimaa S, Ronnberg L, Vuori J. Placebo controlled study on serum concentrations of CA-125 before and after treatment of endometriosis with danazol or high-dose medroxyprogesterone acetate alone or after surgery. Fertility and Sterility 1988;49(1):37-41.
    1. Telimaa S, Poulakka J, Ronnberg L, Kauppila A. Placebo controlled comparison of danazol and high-dose medroxyprogesterone acetate in the treatment of endometriosis. Gynecological Endocrinology 1987;1:13-23.
    1. Telimaa S. Danazol and medroxyprogesterone acetate inefficacious in the treatment of infertility in endometriosis. Fertility and Sterility 1988;50(6):872-5.
Vahid‑Dastjerdi 2023 {published data only}
    1. Vahid-Dastjerdi M, Hosseini R, Rodi H, Rastad H, Hosseini L. Comparison of the effectiveness of Dienogest with medroxyprogesterone acetate in the treatment of pelvic pain and recurrence of endometriosis after laparoscopic surgery. Archives of Gynecology and Obstetrics 2023;308(1):149-55. [PMID: ] - PubMed
Vercellini 2002 {published data only}
    1. Vercellini P, De Giorgi O, Mosconi P, Stellato G, Vicentini S, Crosignani P. Cytoproterone acetate versus a continuous monophasic oral contraceptive in the treatment of recurrent pelvic pain after conservative surgery for symptomatic endometriosis. American Journal of Obstetrics and Gynecology 2002;77(1):52-61.
Vercellini 2005 {published data only}
    1. Vercellini P, Pietropaolo G, De Giorgi O, Pasin R, Chiodini A, Crosignani PG. Treatment of symptomatic rectovaginal endometriosis with an estrogen-progestogen combination versus low-dose norethindrone acetate. Fertility and Sterility 2005;84(5):1375-87. [PMID: ] - PubMed
Walch 2009 {published data only}
    1. Walch K, Unfried G, Huber J, Kurz C, Trotsenburg M, Pernicka E, et al. Implanon versus medroxyprogesterone acetate: effects on pain scores in patients with symptomatic endometriosis - a pilot study. Contraception 2009;79(1):29-34. [PMID: ] - PubMed
Wong 2010 {published data only}
    1. Wong AY, Tang, LCH, Chin RK. Levonorgestrel-releasing intrauterine system (Mirena) and Depot medroxyprogesterone acetate (Depoprovera) as long-term maintenance therapy for patients with moderate and severe endometriosis: a randomised controlled trial. Australian & New Zealand Journal of Obstetrics & Gynaecology 2010;50(3):273-9. [PMID: ] - PubMed
Ylanen 2003 {published data only}
    1. Ylanen K, Laatikainen T, Lahteenmaki P, Moo-Young AJ. Subdermal progestin implant (Nestorone) in the treatment of endometriosis: a clinical response to various doses. Acta Obstetricia et Gynecologica Scandinavica 2003;82(2):167-72. [PMID: ] - PubMed

References to studies excluded from this review

Bromham 1995 {published and unpublished data}
    1. Bromham DR, Booker MW, Rose GL, Wardle PG, Newton JR. A multicentre comparative study of gestrinone and danazol in the treatment of endometriosis. Journal of Obstetrics and Gynaecology 1995;15:188-94.
    1. Bromham DR, Booker MW, Rose GL, Wardle PG, Newton JR. Updating the clinical experience in endometriosis - the European perspective. British Journal of Obstetrics and Gynaecology 1995;102 Suppl 12:12-6.
Carbonell 2016 {published data only}
    1. Carbonell JL, Riveron AM, Leonard Y, Gonzalez J, Heredia B, Sanchez C. Mifeprisone 2.5, 5, 10 mg versus placebo in the treatment of endometriosis. Journal of Reproductive Health and Medicine 2016;2:17-25. [PMID: ] - PMC - PubMed
Cooke 1989 {published data only}
    1. Cooke ID, Thomas EJ. The medical treatment of mild endometriosis. Acta Obstetricia et Gynecologica Scandinavica 1989;68(S150):27-30. [PMID: ] - PubMed
Dawood 1997 {published data only}
    1. Dawood MY, Obasiolu CW, Ramos J, Khan-Dawood FS. Clinical, endocrine, and metabolic effects of two doses of gestrinone in treatment of pelvic endometriosis. American Journal of Obstetrics and Gynecology 1997;176(2):387-94. [PMID: ] - PubMed
Fedele 1989 {published data only}
    1. Fedele L, Arcaini L, Bianchi S, Viezzoli T, Arcaini L, Candiani GB. Gestrinone versus danazol in the treatment of endometriosis. Fertility and Sterility 1989;51(5):781-5.
    1. Fedele L, Bianchi S, Marchini M, Di Nola G. Histological impact of medical therapy-clinical implications. British Journal of Obstetrics and Gynaecology 1995;102 Suppl 12:8-11.
GISG 1996 {published data only}
    1. The Gestrinone Italian Study Group. Gestrinone versus a gonadotropin releasing hormone agonist for the treatment of pelvic pain associated with endometriosis: a multicenter, randomised, double-blind study. Fertility and Sterility 1996;66:911-9.
Halbe 1995 {published data only}
    1. Halbe HW, Nakamura MS, Da Silveira GP, Carvalho WP. Updating the clinical experience in endometriosis - the Brazilian perspective. British Journal of Obstetrics and Gynaecology 1995;102(12):17-21. [PMID: ] - PubMed
Hornstein 1990 {published data only}
    1. Hornstein MD, Glaeson RE, Barbieri RL. A randomised, double-blind prospective trial of two doses of gestrinone in the treatment of endometriosis. Fertility and Sterility 1990;53(2):237-41.
Vercellini 1996 {published data only}
    1. Vercellini P, De Giorgi O, Oldani S, Cortesi I, Panazza S, Crosignani PG. Depot medroxyprogesterone acetate versus an oral contraceptive combined with very-low-dose danazol for long-term treatment of pelvic pain associated with endometriosis. American Journal of Obstetrics and Gynecology 1996;175:396-401.
Yang 2006 {published data only}
    1. Yang DX, Ma WG, Qu F, Ma BZ. Comparative study on the efficacy of Yiweining Gestrinone for Post-operational treatment of Stage III Endometriosis. Chinese Journal of Integrative Medicine 2006;12(3):218-20. [PMID: ] - PubMed

References to studies awaiting assessment

Biswas 2024 {published data only}
    1. Biswa S, Bhattacharyya R, Pramanik SR, Jain N, Biswas SC. Evaluation of efficacy and safety of 2 mg vs 4 mg dienogest in endometriosis: a randomised single-blind dose-ranging trial. Journal of Clinical and Diagnostic Research 2024;18(4):QC01-4. [DOI: 10.7860/JCDR/2024/67933.19297] - DOI
Cooper 2024 {published data only}
    1. Cooper KG, Bhattacharya S, Daniels JP, Cheed V, Gennard L, Leighton L, et al. Preventing recurrence of endometriosis related pain by means of long-acting progestogen therapy: the PRE-EMPT RCT. Health Technology Assessment 2024;28(55):1-77. [DOI: 10.3310/SQWY6998] - DOI
    1. Cooper KG, Bhattacharya S, Daniels JP, Horne AW, Clark TJ, Saridogan E, et al, Middleton LJ, PRE-EMPT Collaborative Group. Long acting progestogens versus combined oral contraceptive pill for preventing recurrence of endometriosis related pain: the PRE-EMPT pragmatic, parallel group, open label, randomised controlled trial. BMJ (Clinical Research Ed.) 2024;385:e079006. [PMID: ] - PMC - PubMed
Harada 2024 {published data only}
    1. Harada T, Kobayashi T, Hirakawa A, Takayanagi T, Nogami M, Mochiyama T, et al. Efficacy and safety of the combination of estetrol 15 mg/drospirenone 3 mg in a cyclic regimen for the treatment of endometriosis-associated pain and objective gynecological findings: a multicenter, placebo-controlled, double-blind, randomized study. Fertility and Sterility 2024;122(5):894-901. [PMID: ] - PubMed
Skhirtladze 2024 {published data only}
    1. Skhirtladze D, Kristesashvili J, Charekishvili R. Efficacy of postsurgical medical therapy for infertile patients with deep endometriosis. Ginekologia Polska 2024;95(11):852-6. [PMID: ] - PubMed

Additional references

Becker 2022
    1. Becker CM, Bokor A, Heikinheimo O, Horne A, Jansen F, Kiesel L, et al, Vermeulen N, ESHRE Endometriosis Guideline Group. ESHRE guideline: endometriosis. Human Reproduction Open 2022;2022(2):hoac009. [PMID: ] - PMC - PubMed
Chen 2016
    1. Chen LC, Hsu JW, Huang KL, Bai YM, Su TP, Cheng-Ta L, et al. Risk of developing major depression and anxiety disorders among women with endometriosis: a longitudinal follow-up study. Journal of Affective Disorders 2016;190:282-5. [DOI: 10.1016/j.jad.2015.10.030] - DOI
Chen 2020
    1. Chen I, Veth VB, Choudhry AJ, Murji A, Zakhari A, Black AY, et al. Pre- and postsurgical medical therapy for endometriosis surgery. Cochrane Database of Systematic Reviews 2020, Issue 11. Art. No: CD003678. [DOI: 10.1002/14651858.CD003678.pub3] [PMID: ] - DOI - PMC - PubMed
Covidence [Computer program]
    1. Covidence. Version accessed 3 June 2024. Melbourne, Australia: Veritas Health Innovation, 2024. Available at https://www.covidence.org.
Davis 2007
    1. Davis L, Kennedy SS, Moore J, Prentice A. Modern combined oral contraceptives for pain associated with endometriosis. Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No: CD001019. [DOI: 10.1002/14651858.CD001019.pub2] - DOI
Deeks 2024
    1. Deeks JJ, Higgins JP, Altman DG, McKenzie JE, Veroniki AA, editor(s). Chapter 10: Analysing data and undertaking meta-analyses (chapter last updated November 2024). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024. Available from www.training.cochrane.org/handbook.
Di Spiezio Sardo 2025
    1. Di Spiezio Sardo A, Becker CM, Renner SP, Suvitie PA, Tarriel JE, Vannuccini S, et al. Management of women with endometriosis in the 21st century. Current Opinion in Obstetrics & Gynecology 2025;37(3):149-157. [DOI: 10.1097/GCO.0000000000001027] [PMID: ] - DOI - PMC - PubMed
Duffy 2020
    1. Duffy J, Hirsch M, Vercoe M, Abbott J, Barker C, Collura B, et al. Endo:outcomes - an International Collaboration Harmonising Outcomes and Outcome Measures for Endometriosis Research. A core outcome set for future endometriosis research: an international consensus development study. BJOG 2020;127(8):967-74.
Fu 2017
    1. Fu J, Song H, Zhou M, Zhu H, Wang Y, Chen H, et al. Progesterone receptor modulators for endometriosis. Cochrane Database of Systematic Reviews 2017, Issue 7. Art. No: CD009881. [DOI: 10.1002/14651858.CD009881.pub2] [PMID: ] - DOI - PMC - PubMed
Gao 2006
    1. Gao X, Outley J, Botteman M, Spalding J, Simon JA, Pashos CL. Economic burden of endometriosis. Fertility and Sterility 2006;86(6):1561-72. [DOI: 10.1016/j.fertnstert.2006.06.015] - DOI
Gibbons 2021
    1. Gibbons T, Georgiou EX, Cheong YC, Wise MR. Levonorgestrel-releasing intrauterine device (LNG-IUD) for symptomatic endometriosis following surgery. Cochrane Database of Systematic Reviews 2021, Issue 12. Art. No: CD005072. [DOI: 10.1002/14651858.CD005072.pub4] [PMID: ] - DOI - PMC - PubMed
GRADEpro GDT [Computer program]
    1. GRADEpro GDT. Version accessed 4 June 2024. Hamilton (ON): McMaster University (developed by Evidence Prime), 2024. Available at gradepro.org.
Higgins 2011
    1. Higgins JP, Green S, editor(s). Chapter 8: Assessing risk of bias in included studies. In: Higgins JP, Green S editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from https://training.cochrane.org/handbook/archive/v5.1/.
Higgins 2021
    1. Higgins JP, Li T, Deeks JJ, editor(s). Chapter 6: Choosing effect measures and computing estimates of effect. In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.2 (updated February 2021). Cochrane, 2021. Available from www.training.cochrane.org/handbook/archive/v6.2.
Higgins 2024
    1. Higgins JP, Savović J, Page MJ, Elbers RG, Sterne JA. Chapter 8: Assessing risk of bias in a randomized trial (chapter last updated October 2019). In: Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 6.5 (updated August 2024). Cochrane, 2024. Available from www.training.cochrane.org/handbook.
Huang 2022
    1. Huang G, Le AL, Goddard Y, James D, Thavorn K, Payne M, et al. A systematic review of the cost of chronic pelvic pain in women. Journal d'Obstetrique et Gynecologie du Canada: JOGC [Journal of Obstetrics and Gynaecology Canada: JOGC 2022;44(3):286-93. [PMID: ] - PubMed
Kistner 1959
    1. Kistner RW. Treatment of endometriosis by inducing pseudo-pregnancy with ovarian hormones. Fertility and Sterility 1959;10:539-54.
Klein 2014
    1. Klein S, D'Hooghe T, Meuleman C, Dirksen C, Dunselman G, Simoens S. What is the societal burden of endometriosis-associated symptoms? A prospective Belgian study. Reproductive Biomedicine Online 2014;28(1):116-24. [DOI: 10.1016/j.rbmo.2013.09.020] - DOI
NICE 2024
    1. National Institute for Health and Care Excellence (NICE). Endometriosis: diagnosis and management (last undated 11 November 2024). https://www.nice.org.uk/guidance/ng73. [PMID: ] - PubMed
Pope 2015
    1. Pope CJ, Shrama V, Sharma S, Mazmanian D. A systematic review of the association between psychiatric disturbances and endometriosis. Journal of Obstetrics and Gynecology of Canada 2015;37(11):1006-15. [DOI: 10.1016/s1701-2163(16)30050-0] - DOI
PRISMA
    1. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ (Clinical Research Ed.) 2021;372:n71. [DOI: 10.1136/bmj.n71] - DOI
RevMan [Computer program]
    1. Review Manager (RevMan). Version 8.1.1. The Cochrane Collaboration, 2024. Available at revman.cochrane.org.
Rodgers 2008
    1. Rodgers AK, Falcone T. Treatment strategies for endometriosis. Expert Opinion on Pharmacotherapy 2008;9(2):243-55.
Schünemann 2013
    1. Schünemann H, Brożek J, Guyatt G, Oxman A, editor(s). Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach (updated October 2013). GRADE Working Group, 2013. Available from https://gdt.gradepro.org/app/handbook/handbook.html 2013.
Shaw 1992
    1. Shaw RW. Treatment of endometriosis. Lancet 1992;340(8830):1267-71. [DOI: 10.1016/0140-6736(92)92960-n] - DOI
Simoens 2012
    1. Simoens S, Dunselman G, Dirksen C, Hummelshoj L, Bokor A, Brandes I, et al. The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres. Human Reproduction (Oxford, England) 2012;27(5):1292-9. [DOI: 10.1093/humrep/des073] - DOI
Singh 2024
    1. Singh SS, Allaire C, Al-Nourhji O, Bougie O, Bridge-Cook P, Duigenan S, et al. Guideline no. 449: diagnosis and impact of endometriosis - a Canadian guideline. Journal d'Obstetrique et Gynecologie du Canada: JOGC [Journal of Obstetrics and Gynaecology Canada: JOGC] 2024;46(5):102450. [PMID: ] - PubMed
Yovich 2020
    1. Yovich JL, Rowlands PK, Lingham S, Sillender M, Srinivasan S. Pathogenesis of endometriosis: look no further than John Sampson. Reproductive Biomedicine Online 2020;40(1):7-11. [DOI: 10.1016/j.rbmo.2019.10.007] - DOI
Zakhari 2020
    1. Zakhari A, Edwards D, Ryu M, Matelski JJ, Bougie O, Murji A. Dienogest and the risk of endometriosis recurrence following surgery: a systematic review and meta-analysis. Journal of Minimally Invasive Gynecology 2020;27(7):1503-10. [PMID: ] - PubMed
Zondervan 2020
    1. Zondervan K, Becker C, Missmer S. Endometriosis. New England Journal of Medicine 2020;382(13):1244-56. [DOI: 10.1056/NEJMra1810764] - DOI

References to other published versions of this review

Brown 2012
    1. Brown J, Kives S, Akhtar M. Progestagens and anti-progestagens for pain associated with endometriosis. Cochrane Database of Systematic Reviews 2012, Issue 3. Art. No: CD002122. [DOI: 10.1002/14651858.CD002122.pub2] - DOI
Prentice 2000
    1. Prentice A, Deary AJ, Bland E. Progestagens and anti-progestagens for pain associated with endometriosis. Cochrane Database of Systematic Reviews 2000, Issue 2. Art. No: CD002122. [DOI: 10.1002/14651858.CD002122] - DOI

Associated data